Among the primary end points , the incidence of deaths from CHD was 3.79 % in the treatment group and 5.49 % in the control group , with a reduction of relative risk by 31.0 % in treatment group ( P < 0.0048 ) ; ( 2 ) The incidence of nonfatal myocardial infarction reduced by 60.8 % in treatment group compared to control group ( 1.93 % vs 4.92 % , P < 0.0000 ) ; ( 3 ) The incidence of the secondary end-points ( stroke , tumor , PCI/CABG ) also decreased by 31.1 % in treatment group compared to control group ( 6.92 % vs 10.04 % P < 0.0004 ) .
